<?xml version="1.0" encoding="UTF-8"?>
<p id="Par60">Several randomized clinical trials (RCTs) are currently underway, not yet published, which are testing different therapies for COVID-19. One of the drugs, normally used in the treatment of rheumatoid arthritis, targets the interleukin 6 receptor and has been included in the COVID-19 treatment guidelines issued by the Chinese National Health Commission [
 <xref ref-type="bibr" rid="CR33">33</xref>, 
 <xref ref-type="bibr" rid="CR34">34</xref>]. In addition, several RCTs are underway regarding the use of antiviral drugs for the treatment of COVID-19 [
 <xref ref-type="bibr" rid="CR32">32</xref>, 
 <xref ref-type="bibr" rid="CR35">35</xref>â€“
 <xref ref-type="bibr" rid="CR38">38</xref>]. Finally, a recent study evaluates the use of plasma from convalescent patients with previous SARS-CoV-2 infection as a potential therapeutic treatment [
 <xref ref-type="bibr" rid="CR39">39</xref>]. Another study shows that the use of systemic corticosteroids for COVID-19 is not recommended [
 <xref ref-type="bibr" rid="CR40">40</xref>].
</p>
